|
Anbei ein aktueller Artikel zu bevorstehenden FDA-Approval-Terminen. Wie bereits im Thread erwähnt soll am 11.2. für DDSS die Stunde der Wahrheit schlagen. Quelle: http://www.todaysfinancialnews.com/investment-strategies/fda… ******************************************************************** Upcoming FDA decision dates… and the companies that may benefit We’ve compiled a list of January and February FDA decision dates – and the companies that could see massive movement in their share price as those dates approach. by Laura Cadden, TodaysFinancialNews.com Baltimore (TFN): Favorable FDA decisions can mean resounding gains for pharma investors… Vanda Pharmaceuticals (NASDAQL:VNDA) experienced an 800% increase in share price when it when the FDA granted approval for Fanapt, a drug to treat schizophrenia, back in May. On Dec. 1, Santarus Inc. (NASDAQ: SNTS) announced its heartburn medication, Zegerid, was approved by the FCA. The Stock went up over 40% in 24 hours. More modest (but still significant) was the 20% increase Dyax Corp. (NASDAQ: DYAX) saw on Dec. 2 when it was announced that the company’s treatment for the genetic disorder hereditary angiodema, Kalbitor, had received FDA clearance. So what company could be next for these kinds of gains? Below is a list of January and February FDA decision dates – and the publicly traded companies that could see massive price movement in their share prices as those dates approach: FDA decision due: Jan. 16, 2010 MannKind Corporation (NASDAQ:MNKD) Regarding: Preliminary approval an inhaled insulation device called Afresa. Share price as of 12/30/2009: $25.40 FDA decision due: Jan. 18, 2010 Roche Holding Ltd. (OTC:RHHBY) Regarding: Approval for the use of Taceva for the treatment of lung cancer in patients already responding to chemotherapy. Share price as of 12/30/2009: $42.18 FDA decision due: Jan. 22, 2010 Acorda Therapeutics (NASDAQ:ACOR) Regarding: New drug application review for Fampridine-SR to be used to improve conduction in nerve fibers when the insulating layer (myelin) has been damaged. Share price as of 12/30/2009: $25.39 FDA decision due: Jan. 30, 2010 Spectrum Pharmaceuticals (NASDAQ:SPPI) Regarding: The results of a meeting with the FDA to discuss the viability of continuing to seek approval for Fusilev for the treatment of colon cancer will be announced. Share price as of 12/30/2009: $4.42 FDA decision due: Feb. 9, 2009 XenoPort, Inc. (NASDAQ:XNPT) Regarding: FDA review results of gabapentin encarbil for the treatment of moderate-to-severe primary Restless Legs Syndrome. Share price as of 12/30/2009: $18.48 FDA decision due: Feb. 11, 2009 Labopharm Inc. (NASDAQ: DDSS) Regarding: Approval of Trazodone Contramid for depression. Share price as of 12/30/2009: $2.03 FDA decision due: Feb. 12, 2009 Cadance Pharmaceuticals (NASDAQ: CADX) Regarding: Approval of acetavance (intravenous acetamenophin) for the treatment of fever and pain. Share price as of 12/30/2009: $9.73 FDA decision due: Feb. 13, 2009 Gilead Sciences (NASDAQ:GILD) Regarding: Approval of Cayston for the treatment of cystic fibrosis. Share price as of 12/30/2009: $43.93 ******************************************************************** |
|
| aus der Diskussion: | Labopharm ....Nur geschenkt ist noch billiger |
| Autor (Datum des Eintrages): | yxcv1234 (07.01.10 18:56:08) |
| Beitrag: | 119 von 324 (ID:38686561) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |